Are serum levels of CD44 relevant in children with pediatric sarcomas?

Kebudi, Rejin; Ayan, İnci̇; Yasasever, Vildan; Demokan, Semra; Görgün, Ömer

doi:10.1002/pbc.20554

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kebudi et al [43] compared serum CD44 levels in children having sarcomas with those in healthy children. There was no statistically significant difference between serum CD44 levels in children with sarcomas and those in healthy children.…”

Section: Introductionmentioning

confidence: 99%

Serum tumor markers in pediatric osteosarcoma: a summary review

et al. 2012

View full text Add to dashboard Cite

Osteosarcoma is the most common primary high-grade bone tumor in both adolescents and children. Early tumor detection is key to ensuring effective treatment. Serum marker discovery and validation for pediatric osteosarcoma has accelerated in recent years, coincident with an evolving understanding of molecules and their complex interactions, and the compelling need for improved pediatric osteosarcoma outcome measures in clinical trials. This review gives a short overview of serological markers for pediatric osteosarcoma, and highlights advances in pediatric osteosarcoma-related marker research within the past year. Studies in the past year involving serum markers in patients with pediatric osteosarcoma can be assigned to one of four categories, i.e., new approaches and new markers, exploratory studies in specialized disease subsets, large cross-sectional validation studies, and longitudinal studies, with and without an intervention.Most of the studies have examined the association of a serum marker with some aspect of the natural history of pediatric osteosarcoma. As illustrated by the many studies reviewed, several serum markers are emerging that show a credible association with disease modification. The expanding pool of informative osteosarcoma-related markers is expected to impact development of therapeutics for pediatric osteosarcoma positively and, it is hoped, ultimately clinical care. Combinations of serum markers of natural immunity, thyroid hormone homeostasis, and bone tumorigenesis may be undertaken together in patients with pediatric osteosarcoma. These serum markers in combination may do better. The potential effect of an intrinsic dynamic balance of tumor angiogenesis residing within a single hormone (tri-iodothyronine) is an attractive concept for regulation of vascularization in pediatric osteosarcoma.

show abstract

Section: Introductionmentioning

confidence: 99%

Serum tumor markers in pediatric osteosarcoma: a summary review

et al. 2012

View full text Add to dashboard Cite

show abstract

Childhood Osteosarcoma: Multimodal Therapy in a Single-Institution Turkish Series

Ayan¹,

Kebudi²,

Özger³

2009

Cancer Treatment and Research

View full text Add to dashboard Cite

Between January 1990 and December 2006, 123 patientsor=90%) was significantly correlated with the 5-year EFS (31% vs. 67.6%, respectively, p=0.023) but not with OS (57.7% vs. 76.5%, respectively, p=0.13). The presence of metastases at diagnosis was found to be the most significant single characteristic influencing the outcome. The rate of histologically good response to preoperative chemotherapy was 64.5%, which is comparable with the 28-85% response rates given in the literature. Our results demonstrate that the combination of epirubicin, cisplatin, and ifosfamide is an active and reasonably well-tolerated regimen for childhood osteosarcoma.

show abstract

CD44 In Sarcomas: A Comprehensive Review and Future Perspectives

2022

View full text Add to dashboard Cite

It is widely accepted that the tumor microenvironment, particularly the extracellular matrix, plays an essential role in the development of tumors through the interaction with specific protein-membrane receptors. One of the most relevant proteins in this context is the transmembrane protein CD44. The role of CD44 in tumor progression, invasion, and metastasis has been well established in many cancers, although a comprehensive review concerning its role in sarcomas has not been published. CD44 is overexpressed in most sarcomas and several in vitro and in vivo experiments have shown a direct effect on tumor progression, dissemination, and drug resistance. Moreover, CD44 has been revealed as a useful marker for prognostic and diagnostic (CD44v6 isoform) in osteosarcoma. Besides, some innovative treatments such as HA-functionalized liposomes therapy have become an excellent CD44-mediated intracellular delivery system for osteosarcoma. Unfortunately, the reduced number of studies deciphering the prognostic/diagnostic value of CD44 in other sarcoma subgroups, neither than osteosarcoma, in addition to the low number of patients involved in those studies, have produced inconclusive results. In this review, we have gone through the information available on the role of CD44 in the development, maintenance, and progression of sarcomas, analyzing their implications at the prognostic, therapeutic, and mechanistic levels. Moreover, we illustrate how research involving the specific role of CD44 in the different sarcoma subgroups could suppose a chance to advance towards a more innovative perspective for novel therapies and future clinical trials.

show abstract

Are serum levels of CD44 relevant in children with pediatric sarcomas?

Abstract: In this study, serum CD44 levels were not found to be of value in the diagnosis or prognosis in children with sarcomas.

Cited by 3 publications

References 23 publications

Serum tumor markers in pediatric osteosarcoma: a summary review

Serum tumor markers in pediatric osteosarcoma: a summary review

Childhood Osteosarcoma: Multimodal Therapy in a Single-Institution Turkish Series

CD44 In Sarcomas: A Comprehensive Review and Future Perspectives

Contact Info

Product

Resources

About